Does genetic diversity of HIV-1 non-B subtypes differentially impact disease progression in treatment-naive HIV-1-infected individuals? A systematic review of evidence: 1996-2010

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 4, 2012, Pages 382-388

  Pai, Nitika Pant ^a   Shivkumar, Sushmita ^a   Cajas, Jorge Martinez ^b  

^a MCGILL UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

ART naive; Differential response; Disease progression; HIV 1 non B subtypes

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; DEATH; DISEASE COURSE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HUMANS; MALE; VIRAL LOAD;

EID: 84859737212     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824a0628     Document Type: Review

References (34)

1. Geretti AM. HIV-1 subtypes: epidemiology and significance fov HIV management. Curr Opin Infect Dis. 2006;19:1-7. (Pubitemid 43032432)
2. Hemelaar J, Gouws E, Ghys PD, et al. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20: W13-W23. (Pubitemid 44611051)
3. Taylor B, Sobieszczyk M, McCutchan F, et al. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008;358:1590-1602.
4. WHO, UN, UNICEF. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report. Geneva, Switzerland: WHO; 2007.
5. Martinez-Cajas J, Pant Pai N, Klein MB, et al. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev. 2008;10:212-223.
6. Holguin A, Soriano V. Resistance to antiretroviral agents in individuals with HIV-1 Non-B subtypes. HIV Clin Trials. 2002;3:403-411. (Pubitemid 35189884)
7. Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol. 2004;29:152-159. (Pubitemid 38201460)
8. Cardoso LP, Stefani MM. High level of multidrug resistance mutations in HIV type 1 pol gene and resistance-associated mutations to enfuvirtide (T-20) among antiretroviral-experienced patients from central Brazil. AIDS Res Hum Retroviruses. 2009;25:943-950.
9. Pant Pai N, Cajas JM, Shivkumar S, et al. In women, do non-B clade differentially impact the odds of developing mutations to single dose nevirapine (sdNVP) for prevention of mother-to-child ttransmission? A hierarchical Bayesian meta-analysis. Presented at: International AIDS Society; 2011; Rome, Italy.
10. Chalermchockcharoenkit A, Culnane M, Chotpitayasunondh T, et al. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV. Clin Infect Dis. 2009;49:299-305.
11. Eshleman SH, Guay LA, Fleming T, et al. Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012). J Acquir Immune Defic Syndr. 2002;31:327-330. (Pubitemid 35278634)
12. Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis. 2006;42:843-852. (Pubitemid 43363943)
13. Amornkul P, Tansuphasawadikul S, Limpakarnjanarat K, et al. Clinical disease associated with HIV-1 subtype B' and E infection among 2104 patients in Thailand. AIDS. 1999;13:1963-1969. (Pubitemid 29509557)
14. Neilson J, John G, Carr J, et al. Subtypes of Human Immunodeficiency Virus Type 1 and disease stage among women in Nairobi, Kenya. J Virol. 1999;73:4393-4403. (Pubitemid 29189886)
15. Kanki P, Hamel D, Sankale JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis. 1999;179: 68-73. (Pubitemid 29028340)
16. Kaleebu P, French N, Mahe C, et al. Effect of Human ImmunodeficiencyVirus (HIV) Type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1 positive persons in Uganda. J Infect Dis. 2002; 185:1244-1250. (Pubitemid 34439131)
17. Kaleebu P, Ross A, Morgan D, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS. 2001;15:293-299. (Pubitemid 32163814)
18. Morgan D, Kaleebu P, Whitworth J, et al. The stability between two HIV-1 RNA measurements one year apart and the relationship with HIV subtype in rural Uganda. Int J STD AIDS. 2001;12:116-121. (Pubitemid 32158678)
19. Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis. 2008;197:707-713. (Pubitemid 351364471)
20. Kiwanuka N, Robb M, Laeyendecker O, et al. HIV-1 viral subtype differences in the rate of CD4+ T-cell decline among HIV seroincident antiretroviral naive persons in Rakai district, Uganda. J Acquir Immune Defic Syndr. 2010;54:180-184.
21. Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis. 2007;195:1177-1180. (Pubitemid 46543449)
22. Kilmarx P, Limpakarnjanarat K, Kaewkungwal J, et al. Disease progression and survival with Human Immunodeficiency Virus Type 1 subtype E infection among female sex workers in Thailand. J Infect Dis. 2000; 181:1598-1606. (Pubitemid 30387750)
23. Laurent C, Bourgeois A, Faye M, et al. No differencei nclinical progression between patients infected with the predominant Human Immunodeficiency Virus Type 1 circulating recombinant form (CRF) 02-AG strain and patients not infected with CRF02-AG, in Western and West- Central Africa: a four-year prospective multicenter study. J Infect Dis. 2002;186:486-492. (Pubitemid 34876257)
24. Mehendale S, Bollinger R, Kulkarni S, et al. Rapid disease progression in Human Immunodeficiency Virus Type 1-infected seroconverters in India. AIDS Res Hum Retroviruses. 2002;18:1175-1179. (Pubitemid 35370605)
25. Costello C, Nelson K, Suriyanon V, et al. HIV-1 subtype E progression among northern Thai couples: traditional and non-traditional predictors of survival. Int J Epidemiol. 2005;34:577-584. (Pubitemid 40852572)
26. Rangsin R, Piyaraj P, Sirisanthana T, et al. The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up. AIDS. 2007;21(suppl 6):S39-S46. (Pubitemid 350158887)
27. Doualla-Bell F, Avalos A, Gaolathe T, et al. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botsawana failing a nelfinavir-containign regimen. Antimicrob Agents Chemother. 2006;50:2210-2213. (Pubitemid 43807546)
28. Essex M. Evolution of the HIV-1 C epidemic in southern Africa and lessons for controlling an uncontrollable virus. Paper presented at: ISSTDR; 2011; Quebec City, Canada.
29. Solomon A, Lane N, Wightman F, et al. Enhanced replicative capacity and pathogenicity of HIV-1 isolated from individuals infected with drugresistant virus and declining CD4+ T-cell counts. J Acquir Immune Defic Syndr. 2005;40:140-148. (Pubitemid 41395711)
30. Troyer RM, Collins KR, Abraha A, et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.J Virol. 2005;79:9006-9018. (Pubitemid 40934811)
31. Prado JG, Prendergast A, Thobakgale C, et al. Replicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rate. J Virol. 2010;84: 492-502.
32. Abraha A, Nankya IL, Gibson R, et al. CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. J Virol. 2009;83:5592-5605.
33. Sagar M, Lavreys L, Baeten JM, et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol. 2003;77:12921-12926. (Pubitemid 37430688)
34. Arien KK, Abraha A, Quinones-Mateu ME, et al. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol. 2005;79:8979-8990. (Pubitemid 40934809)